DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
Status:
Completed
Trial end date:
2020-03-25
Target enrollment:
Participant gender:
Summary
This is a 16 week, phase 4, randomized and placebo controlled trial, investigating the
separate and combined effects of Sodium Glucose coTransporter 2 (SGLT2) inhibition with
dapagliflozin and Glucagon Like peptide-1 (GLP-1) receptor agonism with exenatide on food
intake, body weight and the neural activity in the central satiety and reward circuits in
response to food-related stimuli by blood oxygen level-dependent (BOLD) fMRI in obese type 2
diabetes patients. The investigators hypothesize that treatment with SGLT2 inhibitors is
associated with alterations in central reward and satiety circuits in response to food
related stimuli, leading to increased appetite and food intake. In addition, the
investigators hypothesize that adding a GLP-1 receptor agonist to the treatment with an SGLT2
inhibitor may increase weight loss and prevent the increased food intake during treatment
with SGLT2 inhibitors due to effects on neuronal activity of central satiety and reward
circuits in response to food-related stimuli in obese patients with T2DM.